口服缬更昔洛韦治疗经典型卡波西肉瘤患者的初步研究。
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma.
机构信息
Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
出版信息
J Infect Dis. 2011 Apr 15;203(8):1082-6. doi: 10.1093/infdis/jiq177.
Abstract
We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Kaposi sarcoma (KS)-associated herpesvirus (KSHV), in classic KS. Five human immunodeficiency virus-seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. None of the study subjects showed an objective response; KS progressed in 4 subjects after 1-4 cycles and remained stable in 1 subject after 6 cycles. KS biopsies showed minimal lytic KSHV antigen and gene expression at baseline and no treatment-associated changes. Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective.
摘要
我们在经典型卡波西肉瘤（KS）中进行了一项口服缬更昔洛韦的临床试验，缬更昔洛韦在体外对卡波西肉瘤相关疱疹病毒（KSHV）具有活性。5 名人类免疫缺陷病毒（HIV）阴性参与者接受缬更昔洛韦治疗，最多进行 6 个为期 4 周的周期，剂量用于治疗巨细胞病毒感染。研究对象均未表现出客观反应；4 名参与者在 1-4 个周期后 KS 进展，1 名参与者在 6 个周期后 KS 稳定。KS 活检显示基线时最小的裂解性 KSHV 抗原和基因表达，无治疗相关变化。尽管缬更昔洛韦在这种情况下对 KS 没有活性，但其他针对性更强的抗疱疹病毒策略可能更有效。
相似文献
1
Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma.
J Infect Dis. 2011 Apr 15;203(8):1082-6. doi: 10.1093/infdis/jiq177.
2
High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Blood. 2011 Jun 30;117(26):6977-86. doi: 10.1182/blood-2010-11-317610. Epub 2011 Apr 12.
3
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
J Infect Dis. 2008 Jul 1;198(1):23-30. doi: 10.1086/588820.
4
New approaches to the treatment of human herpesvirus 8-associated disease.
Rev Med Virol. 2008 Sep-Oct;18(5):321-9. doi: 10.1002/rmv.583.
5
Differences in Kaposi sarcoma-associated herpesvirus-specific and herpesvirus-non-specific immune responses in classic Kaposi sarcoma cases and matched controls in Sicily.
Cancer Sci. 2011 Oct;102(10):1769-73. doi: 10.1111/j.1349-7006.2011.02032.x. Epub 2011 Jul 28.
6
Sequential treatment of cytomegalovirus infection or disease with a short course of intravenous ganciclovir followed by oral valganciclovir: efficacy, safety, and pharmacokinetics.
Transpl Infect Dis. 2010 Jun;12(3):204-12. doi: 10.1111/j.1399-3062.2009.00481.x. Epub 2009 Dec 9.
7
Incidence, risk factors, and outcome of cytomegalovirus infection and disease in patients receiving prophylaxis with oral valganciclovir or intravenous ganciclovir after umbilical cord blood transplantation.
Biol Blood Marrow Transplant. 2009 Jun;15(6):730-40. doi: 10.1016/j.bbmt.2009.03.002. Epub 2009 Apr 11.
8
Retrospective review of the incidence of cytomegalovirus infection and disease after liver transplantation in pediatric patients: comparison of prophylactic oral ganciclovir and oral valganciclovir.
Liver Transpl. 2012 Mar;18(3):347-54. doi: 10.1002/lt.22471.
9
Durable remission of both multicentric Castleman's disease and Kaposi's sarcoma with valganciclovir, rituximab and liposomal doxorubicin in an HHV-8-positive, HIV-negative patient.
J Clin Pharm Ther. 2017 Feb;42(1):111-114. doi: 10.1111/jcpt.12472. Epub 2016 Oct 28.
10
Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
J Acquir Immune Defic Syndr. 2002 Dec 1;31(4):384-90. doi: 10.1097/00126334-200212010-00003.
引用本文的文献
1
Modern Approach to Manage Patients With Kaposi Sarcoma.
J Med Virol. 2025 Mar;97(3):e70294. doi: 10.1002/jmv.70294.
2
Riders on the Storm.
Transpl Infect Dis. 2025 Jan-Feb;27(1):e14426. doi: 10.1111/tid.14426. Epub 2024 Dec 28.
3
Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.
Clin Exp Immunol. 2024 Feb 7;215(2):190-201. doi: 10.1093/cei/uxad115.
4
A prospective cohort study identifies two types of HIV+ Kaposi Sarcoma lesions: proliferative and inflammatory.
Int J Cancer. 2023 Dec 15;153(12):2082-2092. doi: 10.1002/ijc.34689. Epub 2023 Aug 21.
5
Endemic Kaposi's Sarcoma.
Cancers (Basel). 2023 Jan 31;15(3):872. doi: 10.3390/cancers15030872.
6
Therapeutic Perspectives in the Systemic Treatment of Kaposi's Sarcoma.
Cancers (Basel). 2022 Jan 18;14(3):484. doi: 10.3390/cancers14030484.
7
Molecular Diagnostics for Ocular Infectious Diseases: LXXVIII Edward Jackson Memorial Lecture.
Am J Ophthalmol. 2022 Mar;235:300-312. doi: 10.1016/j.ajo.2021.12.002. Epub 2021 Dec 16.
8
Recent Advances in Developing Treatments of Kaposi's Sarcoma Herpesvirus-Related Diseases.
Viruses. 2021 Sep 9;13(9):1797. doi: 10.3390/v13091797.
9
Pathogens and Carcinogenesis: A Review.
Biology (Basel). 2021 Jun 15;10(6):533. doi: 10.3390/biology10060533.
10
The Importance of Early Recognition of KSHV-Mediated Syndromes: A Case Report.
Am J Med. 2021 Oct;134(10):e503-e506. doi: 10.1016/j.amjmed.2021.04.015. Epub 2021 May 11.
本文引用的文献
1
KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine.
J Clin Invest. 2010 Apr;120(4):939-49. doi: 10.1172/JCI40567. Epub 2010 Apr 1.
2
Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebo-controlled, crossover trial.
J Infect Dis. 2008 Jul 1;198(1):23-30. doi: 10.1086/588820.
3
Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays.
Cancer Res. 2003 May 1;63(9):2010-5.
4
A pilot study of cidofovir in patients with kaposi sarcoma.
J Infect Dis. 2003 Jan 1;187(1):149-53. doi: 10.1086/346159. Epub 2002 Dec 13.
5
Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study.
J Clin Oncol. 2002 Jan 1;20(1):153-9. doi: 10.1200/JCO.2002.20.1.153.
6
Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy.
J Acquir Immune Defic Syndr. 2000 Jul 1;24(3):270-4. doi: 10.1097/00126334-200007010-00013.
7
Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS.
J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Jan 1;20(1):34-8. doi: 10.1097/00042560-199901010-00005.
8
Foscarnet and AIDS-associated Kaposi's sarcoma.
AIDS. 1997 Nov 15;11(14):1787-8.
9
In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus.
AIDS. 1997 Sep;11(11):1327-32. doi: 10.1097/00002030-199711000-00006.
10
Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.
J Clin Invest. 1997 May 1;99(9):2082-6. doi: 10.1172/JCI119380.
Zotero 插件